On May 29, ResMed declined 5.08% in regular trading, trading at $193.03/share, with trading volume of $276 million. The medical device giant announced a major acquisition to enter a new business segment, triggering negative market reaction.

Investors expressed concerns that the acquisition could introduce significant integration risks and create short-term capital pressure on the company. The stock has already retreated substantially from its 52-week high of $293.81, leaving market sentiment fragile. The broader Health Care Equipment sector traded lower in sympathy, with Medtronic down 1.98%, Boston Scientific down 1.73%, and Abbott Laboratories down 0.66%.

ResMed is a global leader in respiratory medical devices and cloud-based software solutions, primarily focused on diagnosing, treating, and managing sleep-disordered breathing, chronic obstructive pulmonary disease, and other chronic conditions. The company operates through Sleep and Respiratory Care and Software as a Service segments, marketing products to sleep clinics, home healthcare dealers, and hospitals worldwide.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)